+

WO2002069691A3 - Peptides vih immunogenes utilises en tant que reactifs et en tant que vaccins - Google Patents

Peptides vih immunogenes utilises en tant que reactifs et en tant que vaccins Download PDF

Info

Publication number
WO2002069691A3
WO2002069691A3 PCT/US2002/006314 US0206314W WO02069691A3 WO 2002069691 A3 WO2002069691 A3 WO 2002069691A3 US 0206314 W US0206314 W US 0206314W WO 02069691 A3 WO02069691 A3 WO 02069691A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
vaccines
reagents
hiv peptides
immunoreactive
Prior art date
Application number
PCT/US2002/006314
Other languages
English (en)
Other versions
WO2002069691A2 (fr
Inventor
Janet M Mcnicholl
Kyle Bond
Busarawan Sriwanthana
Chou-Pong Pau
Anne Degroot
Original Assignee
Us Gov Health & Human Serv
Janet M Mcnicholl
Kyle Bond
Busarawan Sriwanthana
Chou-Pong Pau
Anne Degroot
Univ Brown Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Janet M Mcnicholl, Kyle Bond, Busarawan Sriwanthana, Chou-Pong Pau, Anne Degroot, Univ Brown Res Found filed Critical Us Gov Health & Human Serv
Priority to CA002439990A priority Critical patent/CA2439990A1/fr
Priority to EP02721225A priority patent/EP1490396A4/fr
Priority to JP2002568886A priority patent/JP2004535369A/ja
Publication of WO2002069691A2 publication Critical patent/WO2002069691A2/fr
Publication of WO2002069691A3 publication Critical patent/WO2002069691A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des peptides VIH immunogènes et des procédés d'utilisation dans lesquels chaque peptide VIH comprend des épitopes immunoréactifs aux lymphocytes T cytotoxiques (CTL) provenant d'individus VIH positif et se lie à des anticorps immunoréactifs avec la structure assemblée de complexe majeur d'histocompatibilité de classe I (CMH). De préférence, le peptide est isolé ou synthétique et contient entre neuf et once résidus d'acide aminé dans des régions spécifiques du génome VIH.
PCT/US2002/006314 2001-03-01 2002-03-01 Peptides vih immunogenes utilises en tant que reactifs et en tant que vaccins WO2002069691A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002439990A CA2439990A1 (fr) 2001-03-01 2002-03-01 Peptides vih immunogenes utilises en tant que reactifs et en tant que vaccins
EP02721225A EP1490396A4 (fr) 2001-03-01 2002-03-01 Peptides hiv immunogenes utilises en tant que reactifs et en tant que vaccins
JP2002568886A JP2004535369A (ja) 2001-03-01 2002-03-01 試薬およびワクチンとして使用するための免疫原性ｈｉｖペプチド

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27256501P 2001-03-01 2001-03-01
US60/272,565 2001-03-01

Publications (2)

Publication Number Publication Date
WO2002069691A2 WO2002069691A2 (fr) 2002-09-12
WO2002069691A3 true WO2002069691A3 (fr) 2004-09-16

Family

ID=23040344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/006314 WO2002069691A2 (fr) 2001-03-01 2002-03-01 Peptides vih immunogenes utilises en tant que reactifs et en tant que vaccins

Country Status (4)

Country Link
EP (1) EP1490396A4 (fr)
JP (1) JP2004535369A (fr)
CA (1) CA2439990A1 (fr)
WO (1) WO2002069691A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0108210A (pt) 2000-02-04 2002-10-22 Univ Duke Vacina contra o vìrus da imunodeficiência humana
ES2572132T3 (es) * 2004-08-17 2016-05-30 Roussy Inst Gustave Nef del VIH mutada para modular la inmunidad
ES2310848T3 (es) * 2004-10-04 2009-01-16 Biovaxim Limited Vacunas de virus enteros inactivados correspondientes a un subtipo para tratar pacientes con la infeccion vih.
PL2392587T3 (pl) 2006-03-10 2016-08-31 Peptcell Ltd Sekwencje i kompozycje peptydów
EP2745845A1 (fr) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux Procédé de prévention ou de traitement d'une infection par VIH
GB201322574D0 (en) * 2013-12-19 2014-02-05 Equigerminal Sa Retroviral peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656788B1 (fr) * 1992-08-07 2006-10-18 Pharmexa Inc. Peptides de liaison de hla, et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AIDS, vol. 14, no. 11, 2000, pages F111 - F115 *
CHUNG H.C. ET AL.: "Competitive inhibition in vivo and skewing of the T cell repertoire of antigen-specific CTL priming by an anti- peptideMHC monoclonal antibody", JOURNAL OF IMMUNOLOGY, vol. 167, 2001, pages 699 - 707, XP002903695 *
DATABASE PROTEIN [online] XP002903693, accession no. NCBI Database accession no. (AAG36866) *
DE BERARDINIS P. ET AL.: "Phage display of peptide epitopes from HIV - 1 elicits strong cytotoxic responses", NATURE BIOTECHNOLOGY, vol. 18, August 2000 (2000-08-01), pages 873 - 876, XP002161760 *
FOUNG S.K. ET AL.: "A monoclonal antibody against HLA - A11 and A24", HUMAN IMMUNOLOGY, vol. 15, no. 3, March 1986 (1986-03-01), pages 316 - 9, XP002903694 *
KIRKSEY T.J. ET AL.: "The structural basis for the increased immunogenicity of two HIV reverse transcriptase peptide variant/class I major histocompatibility complexes", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 52, 1999, pages 37259 - 37264, XP002903696 *
ZHANG Q.J. ET AL.: "Solvent exposed side chains of peptides bound to HLA A*1101 have similar effects on the reactivity of alloantibodies and specific TCR", INTERNATIONAL IMMUNOLOGY, vol. 8, no. 6, June 1996 (1996-06-01), pages 927 - 38, XP008040475 *

Also Published As

Publication number Publication date
EP1490396A4 (fr) 2006-04-19
CA2439990A1 (fr) 2002-09-12
WO2002069691A2 (fr) 2002-09-12
EP1490396A2 (fr) 2004-12-29
JP2004535369A (ja) 2004-11-25

Similar Documents

Publication Publication Date Title
BR9812139A (pt) Vacina
JP2003528887A5 (fr)
WO1999033868A3 (fr) Vaccin
WO1998056919A3 (fr) Procede reactif de vaccination permettant de generer une reponse immunitaire de cellules t cd8
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
CA2363947A1 (fr) Peptides, antigenes du vih, compositions de vaccins afferentes, trousse de dosage immunologique et methode de detection d'anticorps induits par le vih
WO2010022740A3 (fr) Polypeptides d’enveloppe du vih-1 pour un vaccin contre le vih
CA2389206A1 (fr) Activation de lymphocytes t specifiques au virus de l'hepatite c
EP1461079B8 (fr) Mutants de glycoproteines d'enveloppe du vih et leurs utilisations
Sattentau et al. Antibody neutralization of HIV-1 and the potential for vaccine design
WO2002068654A3 (fr) Poxvirus recombine pour proteines chimeres du virus de l'immunodeficience humaine
WO2003087757A3 (fr) Glycoproteines de l'enveloppe du virus d'immunodeficience humaine liees a des particules, compositions et procedes associes
WO2002069691A3 (fr) Peptides vih immunogenes utilises en tant que reactifs et en tant que vaccins
CA2554195A1 (fr) Peptide provenant du recepteur du facteur de croissance epidermique (egfr)
AU5423898A (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
Bartnes et al. A retro‐inverso analog mimicks the cognate peptide epitope of a CD4+ T cell clone
WO2004041842A3 (fr) Epitopes du virus de l'hepatite c
WO2003029285A3 (fr) Identification de nouveaux epitopes cd8 des proteines du vih-1 presentant des proprietes therapeutiques et vaccinales contre les infection par le vih
WO2001049712A3 (fr) Vaccin destine a la prevention et/ou la prophylaxie de l'anemie infectieuse du saumon chez des poissons
CA2431881A1 (fr) Polypeptide induisant des anticorps neutralisant le vih
WO2004056316A3 (fr) Vaccins contre la proteine tat de vih servant a generer des anticorps neutralisants
WO2000058438A3 (fr) Peptides a contrainte de conformation
WO2004052933A3 (fr) Presentations peptidiques pour des vaccins contre le virus de l'immunodeficience humaine
Wahren et al. Immune responses to the HIV rev regulatory gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002252166

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002568886

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2439990

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002721225

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002721225

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002721225

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载